Insulin Therapy in Type 2 Diabetic Patients: Real-life Study on Effectiveness and Satisfaction

Launched by ASSIUT UNIVERSITY · Nov 2, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating how effective insulin therapy is for people with type 2 diabetes in real-life situations and how satisfied patients are with this treatment. Type 2 diabetes is a condition where the body doesn’t use insulin properly, leading to high blood sugar levels. Researchers want to understand the differences in treatment outcomes between patients starting insulin therapy and those using oral medications.

To participate in this study, you need to be at least 18 years old and have a previous diagnosis of type 2 diabetes. It’s important that you haven't used any insulin products in the past year. Unfortunately, those with type 1 diabetes, pregnant individuals, or anyone who is participating in another clinical trial won’t be eligible. If you join the trial, you can expect to answer some questionnaires about your experience with the treatment. This study is not yet recruiting participants, but it aims to gather valuable insights that could help improve diabetes care in the future, especially in areas like Egypt, where the number of people with diabetes is rising.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • -Patients with type 2 diabetes mellitus aged ≥18 years.
• • Patients going on insulin therapy versus patients going on oral antidiabetic drugs.
• • patients included if they met the following
• Criteria:
• • previous diagnosis of diabetes mellitus or on medical therapy of DM.
• • no prescription fills for a basal insulin containing product in the 1-year pre index date period; and no prescription fills for bolus insulin or mixed insulin products on index date or in the 1-year pre-index date periods.
• Exclusion Criteria:
• • Patients had type 1 diabetes mellitus.
• • Pregnant patients.
• • Incapable of completing the study questionnaires.
• • were pregnant at any time during the pre-or post-index periods; or
• • were diagnosed with any other type of diabetes during the study period, including, gestational diabetes , secondary diabetes , or other abnormal glu-cose conditions .
• • Patients who were con-comitantly participating in another trial or receiving insulin treatment for reasons other than T2DM.